Company: APXIF
Filing Date: 2025-06-11
Form Type: 10-Q
Source: 0001213900-25-053185
Chunk: 48

Company: APx Acquisition Corp. I
Filing Date: 2025-06-11
Form: 10-Q
Item: Part I, Item 1
Chunk 48
---
SPAC Ordinary Share”) outstanding will be exchanged for the right
to receive one ordinary share of OmnigenicsAI, nominal value $0.0001 per share (“Company Share”), (b) all warrants to purchase
SPAC Ordinary Shares (“SPAC Warrants”) will become warrants of OmnigenicsAI (“Company Warrants”) exercisable for
Company Shares, on substantially the same terms as the SPAC Warrants and (c) OmnigenicsAI shall enter into an Assignment, Assumption
and Amendment Agreement with the Company and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent,
to amend and assume the Company’s obligations under the existing Warrant Agreement, dated December 6, 2021, to give effect
to the conversion of SPAC Warrants to Company Warrants.

Conditions to Each Party’s Obligations

The obligations of the
parties to consummate the Proposed Business Combination are subject to the satisfaction or waiver of customary closing conditions at or
prior to the Closing, including (a) approval by the Company’s shareholders; (b) effectiveness of the registration statement
on Form F-4 relating to Company Shares and Company Warrants to be issued in the Merger; (c) Nasdaq listing approval of
the Company Shares and Company Warrants; (d) absence of any law, rule, regulation, judgment, decree, executive order or award which
is then in effect and has the effect of making the Proposed Business Combination illegal or otherwise prohibiting consummation of the
Proposed Business Combination; and I the Company or OmnigenicsAI having at least $5,000,001 of net tangible assets.

The obligation of the
Company to consummate the Proposed Business Combination is subject to certain additional conditions at or prior to the Closing, including
(a) the accuracy of certain representations and warranties of OmnigenicsAI, MultiplAI and Merger Sub except, with respect to certain
representations and warranties required to be true and correct in all respects, where the failure of such representations and warranties
to be true and correct does not result in a Company Material Adverse Effect or MultiplAI Material Adverse Effect or is not materially
adverse to Merger Sub, as applicable; (b) OmnigenicsAI’s and Merger Sub’s performance or compliance in all material respects
with all agreements and covenants required by the Business Combination Agreement; (